Literature DB >> 7532281

Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations.

N Asai1, T Iwashita, M Matsuyama, M Takahashi.   

Abstract

Transforming activity of the c-ret proto-oncogene with multiple endocrine neoplasia (MEN) 2A mutations was investigated by transfection of NIH 3T3 cells. Mutant c-ret genes driven by the simian virus 40 or cytomegalovirus promoter induced transformation with high efficiencies. The 170-kDa Ret protein present on the cell surface of transformed cells was highly phosphorylated on tyrosine and formed disulfide-linked homodimers. This result indicated that MEN 2A mutations induced ligand-independent dimerization of the c-Ret protein on the cell surface, leading to activation of its intrinsic tyrosine kinase. In addition to the MEN 2A mutations, we further introduced a mutation (lysine for asparaginic acid at codon 300 [D300K]) in a putative Ca(2+)-binding site of the cadherin-like domain. When c-ret cDNA with both MEN 2A and D300K mutations was transfected into NIH 3T3 cells, transforming activity drastically decreased. Western blot (immunoblot) analysis revealed that very little of the 170-kDa Ret protein with the D300K mutation was expressed in transfectants while expression of the 150-kDa Ret protein retained in the endoplasmic reticulum was not affected. This result also demonstrated that transport of the Ret protein to the plasma membrane is required for its transforming activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532281      PMCID: PMC230385          DOI: 10.1128/MCB.15.3.1613

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  28 in total

1.  Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence.

Authors:  M Takahashi; Y Buma; H Hiai
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

2.  Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype.

Authors:  J Woolford; A McAuliffe; L R Rohrschneider
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

3.  Developmental expression of the RET protooncogene.

Authors:  V Avantaggiato; N A Dathan; M Grieco; N Fabien; D Lazzaro; A Fusco; A Simeone; M Santoro
Journal:  Cell Growth Differ       Date:  1994-03

4.  Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues.

Authors:  T Tsuzuki; M Takahashi; N Asai; T Iwashita; M Matsuyama; J Asai
Journal:  Oncogene       Date:  1995-01-05       Impact factor: 9.867

5.  Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

Authors:  C Eng; D P Smith; L M Mulligan; M A Nagai; C S Healey; M A Ponder; E Gardner; G F Scheumann; C E Jackson; A Tunnacliffe
Journal:  Hum Mol Genet       Date:  1994-02       Impact factor: 6.150

6.  Mutations of the RET proto-oncogene in Hirschsprung's disease.

Authors:  P Edery; S Lyonnet; L M Mulligan; A Pelet; E Dow; L Abel; S Holder; C Nihoul-Fékété; B A Ponder; A Munnich
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

7.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.

Authors:  G Romeo; P Ronchetto; Y Luo; V Barone; M Seri; I Ceccherini; B Pasini; R Bocciardi; M Lerone; H Kääriäinen
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

8.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC.

Authors:  L M Mulligan; C Eng; C S Healey; D Clayton; J B Kwok; E Gardner; M A Ponder; A Frilling; C E Jackson; H Lehnert
Journal:  Nat Genet       Date:  1994-01       Impact factor: 38.330

9.  A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential.

Authors:  M F Roussel; J R Downing; C W Rettenmier; C J Sherr
Journal:  Cell       Date:  1988-12-23       Impact factor: 41.582

10.  Germ line mutations of the ret proto-oncogene in Japanese patients with multiple endocrine neoplasia type 2A and type 2B.

Authors:  S Maruyama; T Iwashita; T Imai; H Funahashi; I Ceccherini; Y Luo; G Romeo; S Matsuo; M Matsuyama; M Takahashi
Journal:  Jpn J Cancer Res       Date:  1994-09
View more
  67 in total

1.  Identification of a key motif that determines the differential surface levels of RET and TrkB tyrosine kinase receptors and controls depolarization enhanced RET surface insertion.

Authors:  Xue-Zhi Li; Jing Yan; Shu-Hong Huang; Ling Zhao; Jue Wang; Zhe-Yu Chen
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

2.  Review.

Authors:  Sujal Rangwalla; Cheryl E Gariepy
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

3.  Ultraviolet light induces redox reaction-mediated dimerization and superactivation of oncogenic Ret tyrosine kinases.

Authors:  M Kato; T Iwashita; K Takeda; A A Akhand; W Liu; M Yoshihara; N Asai; H Suzuki; M Takahashi; I Nakashima
Journal:  Mol Biol Cell       Date:  2000-01       Impact factor: 4.138

4.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease.

Authors:  F Carlomagno; G De Vita; M T Berlingieri; V de Franciscis; R M Melillo; V Colantuoni; M H Kraus; P P Di Fiore; A Fusco; M Santoro
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

5.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

Review 6.  [Molecular biology, basic research and diagnosis of Hirschsprung's disease].

Authors:  G Martucciello; O Luinetti; P Romano; U Magrini
Journal:  Pathologe       Date:  2007-03       Impact factor: 1.011

7.  Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.

Authors:  S Dvorakova; E Vaclavikova; J Duskova; P Vlcek; A Ryska; B Bendlova
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

8.  Mutations in the extracellular domain cause RET loss of function by a dominant negative mechanism.

Authors:  M P Cosma; M Cardone; F Carlomagno; V Colantuoni
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

9.  Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.

Authors:  A Bardelli; P Longati; D Gramaglia; C Basilico; L Tamagnone; S Giordano; D Ballinari; P Michieli; P M Comoglio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 10.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.